argenx reports trial results: what it means for argenx stock
Published on 10/17/2026 at 11:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical milestones and dates
- On October 8, 2026, argenx announced positive Phase 2 FB102 results in celiac disease.
- A conference call on October 22, 2026, at 2:30 p.m. CET will cover third-quarter results and a business update.
- The next Xetra session is scheduled for October 19, 2026.
argenx announced positive topline results from its Phase 2 FB102 study in adults with celiac disease on October 8, 2026. The study met its primary endpoint, according to the argenx release distributed by GlobeNewswire.
Market context: Market report AEX.
Weekend trading
October 17, 2026 is a non-Xetra trading day for the German market perspective. The next price is shown from the start of trading by the continuously updated real-time quote of argenx stock.
The week in figures
The reviewed company updates were dated October 8 and October 15, 2026. The October 8 announcement covered Phase 2 FB102 results, while the October 15 notice set the date for the next financial update.
Chronology of the week
On October 8, 2026, argenx reported that the FB102 study met its primary endpoint, with a p-value of 0.0176. The study enrolled 126 patients. The findings were reported in the company announcement.
On October 15, 2026, argenx announced that it will discuss third-quarter 2026 financial results and provide a business update during a conference call and webcast on October 22, 2026, at 2:30 p.m. CET. The date and time were provided in the issuer's release.
Dates of the coming week
The next Xetra session is October 19, 2026. argenx has scheduled its third-quarter 2026 results and business update for October 22, 2026, at 2:30 p.m. CET, according to the company's announcement.
